ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 05 Feb 2018
Last Updated on 05 Feb 2018
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Ivabradine 5mg and 7.5mg tablets for the treatment of chronic heart failure in patients:
    • with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less);
    • who are in sinus rhythm with a heart rate of 75 bpm or more and
    • who are given concomitant standard medical management with maximum tolerated doses of beta blockers, angiotensin-converting enzyme inhibitors and aldosterone antagonists, unless contraindicated.

Subsidy status
Ivabradine 5mg and 7.5mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF assistance does not apply to the use of ivabradine for chronic stable angina.

Ivabradine for the treatment of CSA and CHF (5 Feb 2018)